title: Effects of topical travoprost 0.004% on intraocular pressure and corneal biomechanical properties in an animal model.
abstract: OBJECTIVE
  To determine whether topical application of travoprost 0.004% induces changes in corneal biomechanical properties affecting intraocular pressure (IOP) values in rabbits.
  
  
  METHODS
  Both eyes of 10 New Zealand rabbits were measured 3 times with the Ocular Response Analyzer (ORA) before treatment. Each measurement included corneal hysteresis (CH), corneal resistance factor (CRF), corneal-corrected IOP (IOPcc), and Goldmann equivalent IOP (IOPg). A drop of travoprost 0.004% was applied once daily in right eyes for 3 months; left eyes received no treatments. After 3 months of treatment both eyes of all rabbits were again measured 3 times. After complete keratectomy of both eyes, tissues prepared with hematoxylin-eosin stain were analyzed by means of light microscopy.
  
  
  RESULTS
  The mean pre- and post-treatment IOPg, respectively, for right eyes was 9.92 ± 5.64 mm Hg and 7.62 ± 2.99 mm Hg (P = 0.027); IOPcc, 19.81 ± 5.25 mm Hg and 17.79 ± 4.09 mm Hg (P = 0.063); CRF, 1.65 ± 1.63 mm Hg and 2.18 ± 2.50 mm Hg (P = 0.266); and CH, 2.79 ± 1.74 mm Hg and 2.64 ± 2.08 mm Hg (P = 0.72). Mean post-treatment right and left eye IOPg values were, respectively, 7.62 ± 2.99 and 10.30 ± 4.40 (P = 0.002); IOPcc, 17.79 ± 4.09 mm Hg and 20.37 ± 4.32 mm Hg (P = 0.009); CRF, 1.65 ± 1.63 mm Hg and 2.17 ± 2.47 mm Hg (P = 0.274); and CH, 2.79 ± 1.74 mm Hg and 2.54 ± 2.08 mm Hg (P = 0.575). No difference in CH and CRF was observed between treated and untreated eyes.
  
  
  CONCLUSIONS
  Post-treatment reduction of IOP in treated eyes was a direct hypotensive effect of travoprost 0.004% and was not affected by changes in corneal biomechanical properties (CH and CRF), resulting in real lower IOP values.
authors.affiliation: Glaucoma Department, Asociación para Evitar la Ceguera en Mexico I.A.P., San Lucas Coyoacan, Mexico DF;
authors.forename: Gabriel
authors.initials: G
authors.lastname: Lazcano-Gomez
authors.affiliation: Retina Department, Asociación para Evitar la Ceguera en Mexico I.A.P., San Lucas Coyoacan, Mexico DF;
authors.forename: David
authors.initials: D
authors.lastname: Ancona-Lezama
authors.affiliation: Asociación para Evitar la Ceguera en Mexico I.A.P., San Lucas Coyoacan, Mexico DF.
authors.forename: Felix
authors.initials: F
authors.lastname: Gil-Carrasco
authors.affiliation: Glaucoma Department, Asociación para Evitar la Ceguera en Mexico I.A.P., San Lucas Coyoacan, Mexico DF;
authors.forename: Jesus
authors.initials: J
authors.lastname: Jimenez-Roman
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001696:Biomechanical Phenomena; D003315:Cornea / Q000187:drug effects / Q000503:physiopathology*; D004195:Disease Models, Animal; D005901:Glaucoma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects*; D009883:Ophthalmic Solutions; D011817:Rabbits; D014065:Tonometry, Ocular; D000069557:Travoprost / Q000008:administration & dosage*
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D000069557:Travoprost